Cargando…
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
BACKGROUND: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of the still dismal prognosis, further improvements are desperately needed, especi...
Autores principales: | Festuccia, Claudio, Mancini, Andrea, Colapietro, Alessandro, Gravina, Giovanni Luca, Vitale, Flora, Marampon, Francesco, Delle Monache, Simona, Pompili, Simona, Cristiano, Loredana, Vetuschi, Antonella, Tombolini, Vincenzo, Chen, Yi, Mehrling, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830080/ https://www.ncbi.nlm.nih.gov/pubmed/29486795 http://dx.doi.org/10.1186/s13045-018-0576-6 |
Ejemplares similares
-
Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
por: Festuccia, C., et al.
Publicado: (2018) -
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
por: Gravina, Giovanni Luca, et al.
Publicado: (2017) -
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma
por: Colapietro, Alessandro, et al.
Publicado: (2021) -
The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models
por: Gravina, Giovanni Luca, et al.
Publicado: (2019) -
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models
por: Gravina, Giovanni Luca, et al.
Publicado: (2019)